Stock GRI GRI BIOPAR
Add to a list
To use this feature you must be a member
Log inSign up

News GRI BIOPAR

Equities

GRI

US3622AW1069

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.43 USD -0.05% Intraday chart for GRI BIOPAR -18.55% -93.58%
Apr. 16 GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments MT
2023 Vallon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
AQ
GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments
MT
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
AQ
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
AQ
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
AQ
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
AQ
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
AQ
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
AQ
GRI Bio Announces Pricing of $5.5 Million Public Offering
AQ
Vallon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
VALLON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Vallon Pharmaceuticals, GRI Bio Complete Merger
MT
Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.
AQ
VALLON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Vallon Pharmaceuticals' Stockholders Approve Merger With GRI Bio, Reverse Stock Split
MT
Vallon Pharmaceuticals, Inc.(NasdaqCM:VLON) dropped from NASDAQ Composite Index
CI
Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split
AQ
GRI Bio, Inc. completed the acquisition of Vallon Pharmaceuticals, Inc. from group of shareholders in a reverse merger transaction.
CI
VALLON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GRI Stock
  4. News GRI BIOPAR